Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14476349 | 0.81 | MEN1 (0.37) | MEN1MAPK1KMT2AFOLH1DPP8 | |
| SCHEMBL19966403 | 0.81 | MEN1 (0.33) | MEN1MAPK1KMT2AFOLH1DPP8 | |
| SCHEMBL19953322 | 0.80 | MEN1 (0.33) | MEN1MAPK1KMT2AFOLH1DPP8 | |
| SCHEMBL29935596 | 0.78 | TDP1 (0.37) | MEN1MAPK1KMT2AFOLH1DPP8 | |
| SCHEMBL29709304 | 0.78 | MEN1 (0.37) | MEN1MAPK1KMT2AFOLH1DPP8 | |
| SCHEMBL19953443 | 0.76 | FOLH1 (0.33) | MEN1MAPK1KMT2AFOLH1DPP8 | |
| SCHEMBL19966582 | 0.76 | DPP8 (0.31) | MEN1MAPK1KMT2AFOLH1DPP8 | |
| SCHEMBL29419561 | 0.76 | CTSL (0.39) | MEN1MAPK1KMT2AFOLH1DPP8 | |
| SCHEMBL16244106 | 0.76 | MEN1 (0.34) | MEN1MAPK1KMT2AFOLH1DPP8 | |
| SCHEMBL15979034 | 0.75 | MEN1 (0.37) | MEN1MAPK1KMT2AFOLH1DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018047081-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2018-03-15 | — | — | WO | disclosed |